Investigators developed a droplet digital PCR assay targeting driver mutations and found that changes in circulating DNA were correlated with response to radiation.
The agency issued draft guidance on minimal residual disease as a biomarker and finalized another guidance on developing drugs with pan-cancer indications.
The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
The new RNA sequencing analysis workflow integrates Roche's RNA-seq library kits with Genialis' automated data processing pipeline for gene expression analyses.
DNA quantification and normalization are required in most genomics workflows, and are usually routinely implemented after the initial nucleic acid purification step. The versatility of the classical absorbance technique still makes it the go-to method for many applications, as the concentration of all DNA and RNA types can be determined using the specific empiric extinction coefficient for each nucleic acid type.
Quantitative PCR (qPCR) is a preferred method for quantification of low amounts of DNA or cDNA due to its high sensitivity, specificity and reproducibility. Consistently high and uniform qPCR efficiencies are crucial for accurate relative quantification of gene expression levels, low copy gene detection or absolute quantification of NGS libraries1.
Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.
In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.
